Title |
VARIATION IN THE YAK CALPASTATIN GENE (CAST) |
| Genetics Vol:4 Iss:1 (2012-03-15) : 72-73 |
Authors |
HICKFORD J.G.H., YANG G., ZHOU H., HU J., LUO Y. |
Published on |
15 Mar 2012 Pages : 72-73 Article Id : BIA0000209 Views : 1128 Downloads : 1541 |
DOI | http://dx.doi.org/10.9735/0975-2862.4.1.72-73 |
|
Abstract |
Full Text |
PDF | XML |
PubMed XML |
CNKI |
Cited By |
Open Access |
Calpastatin (CAST) is a specific inhibitor of calpain (calcium-dependent cysteine protease). This study investigated the potential
for variation in yak (Bos grennies) CAST. PCR-SSCP analysis of exon 6 of yak CAST revealed three unique patterns (named A-C). Sequencing
of the amplicons revealed two nucleotide substitutions. One substitution (c.398G/C) would nominally change the amino acid sequence
(p.S133T) of yak calpastatin. The variant sequence A which carried c.398C was the most common in the yaks tested (95.1%). This
is the first report that found yak CAST is variable, and as in pigs, sheep and cattle, this variation may affect animal production traits.
|
|
Title |
REVIEW ARTICLE ON GENE THERAPY |
| Genetics Vol:4 Iss:1 (2012-03-15) : 74-79 |
Authors |
PATIL P.M., CHAUDHARI P.D., MEGHA SAHU, DURAGKAR N.J. |
Published on |
15 Mar 2012 Pages : 74-79 Article Id : BIA0000210 Views : 4806 Downloads : 2795 |
DOI | http://dx.doi.org/10.9735/0975-2862.4.1.74-79 |
|
Abstract |
Full Text |
PDF | XML |
PubMed XML |
CNKI |
Cited By |
Open Access |
Gene therapy can be broadly defined as the transfer of genetic material to cure a disease or at least to improve the clinical status of a patient. One of the basic concepts of gene therapy is to transform viruses into genetic shuttles, which will deliver the gene of interest into the target cells. Based on the nature of the viral genome, these gene therapy vectors can be divided into RNA and DNA viral vectors. The majority of RNA virus-based vectors have been derived from simple retroviruses like murine leukemia virus. A major shortcoming of these vectors is that they are not able to transducer nondividing cells. This problem may be overcome by the use of novel retroviral vectors derived from lentiviruses, such as human immunodeficiency virus (HIV). The most commonly used DNA virus vectors are based on adenoviruses and adeno-associated viruses. An example of gene-knockout mediated gene therapy is the knockout of the human CCR5 gene in T-cells in order to control HIV infection[1] Although the available vector systems are able to deliver genes in vivo into cells, the ideal delivery vehicle has not been found. Thus, the present viral vectors should be used only with great caution in human beings and further progress in vector development is necessary.
|